Cost-Minimization/Cost-Consequence (CMA/CCA)
-
Conferences
- Upcoming Conferences
- Past Conferences
- Register
- Submit Abstract
- Exhibits & Sponsorships
- Awards & Grants
-
Education & Training
- In-Person Training
-
Virtual Training
-
Distance Learning
- Introduction to Outcomes Research
- Introduction to Systematic Reviews & Meta-Analysis
- Systematic Review & Meta-Analysis: Applications
- Introduction to Pharmacoeconomics
- Cost-of-Illness/Cost-Estimation (COI/CE)
- Cost-Minimization/Cost-Consequence (CMA/CCA)
- Cost-Effectiveness Analysis (CEA) and Cost-Utility Analysis (CUA)
- Modeling Health Care Costs – Part I: Characteristics of Health Care Costs
- Modeling Health Care Costs – Part II: Methods and Guidelines for Estimating Health Care Costs
- Modeling Health Care Costs – Part III: Estimation from Censored Data
- Introduction to Budget Impact Analysis (BIA) - Part I
- Introduction to Budget Impact Analysis (BIA) - Part II
- Markov Model Toolkit: Concepts, Assumptions and Examples
- An Introduction to Choice-Based Conjoint Analysis (Discrete Choice Experiments)
- Health-Related Quality of Life (HRQOL) – Basics
- Patient Reported Outcomes: Analysis and Interpretation
- Patient Reported Outcomes: Instrument Development
- Item Response Theory: A Conceptual Introduction
- Preparing for Multinational Clinical Trials: Translation and Cultural Adaptations of PRO Measures
- Evidence Generation for Patient Reported Outcome (PRO) Label Claims (FDA Requirements)
- Intermediate Retrospective Observational Study - Propensity Scoring Methods
- Use of Public Survey Data in Health Outcomes Research
-
Webinars
- Using RWE to Improve Healthcare Decision-making in Asia Pacific
- Top 10 HEOR Trends of 2019
- The Use of MCDA for HTA Agencies
- MCDA - How to Guide of Different Methods for Assessment of Rare Disease HT
- Virtualizing Long-Term Follow-Up Studies for Gene Therapy Products
- Is the FDA's New Guidance a Watershed Moment for Real-world Evidence?
- Topics in Evaluating the Cost-Effectiveness of Gene Therapies
-
Distance Learning
-
Calendar
Faculty
Course Description
This module is an introduction to the role of cost-consequence (CC)/cost-minimization analysis(CMA) in medical decision making from multiple perspectives. It will describe situations in which CCA/CMA is the acceptable method of pharmacoeconomic (PE) analysis, the components included, computational methods, the concept of efficacy vs. effectiveness and establishing equivalent outcomes.
Learning Objectives
By the end of the Cost-Minimization/Cost-Consequence (CMA/CCA) module, you will be able to:
- State the role of cost-consequence (CC)/cost-minimization analysis (CMA) in medical decision making.
- Contrast the price of a drug product and the cost of drug therapy.
- Define the components of CC/CMA.
- Understand the computations involved in CC/CMA.
- Understand the concerns in attribution of cost components to a particular treatment arm.
- Summarize the resources used in a therapy or service and assign monetary values to those resources.
- Analyze the value for money from health technologies.
- Summarize how CC/CMA are used in health policy decisions regarding government approval of and reimbursement for therapies.
- Use and apply sensitivity analyses and discounting techniques in CC/CMA.
- Explain how point of view and perspective affect CC/CMA.